CapForce 

$6.06
46
-$0.84-12.17% 20:10 Today

Statistics

Day High
8.5
Day Low
6.05
52W High
34
52W Low
0.0005
Volume
1,480
Avg. Volume
1,394
Mkt Cap
75.13M
P/E Ratio
2.17
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 18Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.4
-1.07
-0.73
-0.4
Expected EPS
N/A
Actual EPS
N/A

Financials

77.75%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
30.2MRevenue
23.48MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.99B
Guardant Health, Inc. specializes in liquid biopsies and cancer diagnostics, directly competing with Opgen's diagnostic solutions for detecting pathogens and antibiotic resistance genes.
Illumina
ILMN
Mkt Cap35.63B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, competing in the broader market of genomic analysis where Opgen also operates.
Qiagen NV
QGEN
Mkt Cap10.37B
Qiagen N.V. offers sample to insight solutions including infectious disease diagnostics, directly competing with Opgen's focus on molecular diagnostics.
Thermo Fisher Scientific
TMO
Mkt Cap257.71B
Thermo Fisher Scientific Inc. offers a wide range of diagnostics and research solutions, including those for infectious disease, competing with Opgen's diagnostic products.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences of California, Inc. provides sequencing systems that compete with Opgen's genomic analysis technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics, Inc. is involved in CRISPR technology for genetic editing, which could compete with Opgen's genomic approaches for diagnostics and treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, potentially competing with Opgen's treatments and diagnostics in genetic diseases.
Adaptive Biotechnologies
ADPT
Mkt Cap4.25B
Adaptive Biotechnologies Corp. focuses on the immune-driven medicine space, including diagnostics that could compete with Opgen's offerings in infection and resistance detection.

About

CapForce Inc. operates as a capital markets advisory and financial technology company. The company offers services including listing consultancy, sponsorship services, and operates the CapForce EC platform. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. The company was incorporated in 2001 and is headquartered in Clarksburg, Maryland.
Show More
CEO
Mr. Christian-Laurent Benoit Bonte
Employees
3
Country
United Kingdom
ISIN
US68373L5057
WKN
000A3D38S

Listings

0 Comments

Share your thoughts

FAQs

What is CapForce stock price today?▼
The current price of CFOR is $6.06 USD — it has decreased by -12.17% in the past 24 hours. Watch CapForce stock price performance more closely on the chart.
What is CapForce stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange CapForce stocks are traded under the ticker CFOR.
Is CapForce stock price growing?▼
CFOR stock has fallen by -32.67% compared to the previous week, the month change is a +49.63% rise, over the last year CapForce has showed a +52.45% increase.
What is CapForce market cap?▼
Today CapForce has the market capitalization of 75.13M
When is the next CapForce earnings date?▼
CapForce is going to release the next earnings report on November 18, 2026.
What is CapForce revenue for the last year?▼
CapForce revenue for the last year amounts to 30.2M USD.
What is CapForce net income for the last year?▼
CFOR net income for the last year is 23.48M USD.
How many employees does CapForce have?▼
As of November 5, 2026, the company has 3 employees.
In which sector is CapForce located?▼
CapForce operates in the Finance & Payments sector.
When did CapForce complete a stock split?▼
CapForce has not had any recent stock splits.
Where is CapForce headquartered?▼
CapForce is headquartered in Clarksburg, United Kingdom.